Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.

Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin
{"title":"Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.","authors":"Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin","doi":"10.1080/09546634.2025.2460582","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.</p><p><strong>Materials and methods: </strong>We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.</p><p><strong>Results: </strong>In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.</p><p><strong>Conclusions: </strong>This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460582"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2460582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.

Materials and methods: We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.

Results: In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.

Conclusions: This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.

扩大司匹利单抗的治疗范围:对炎症性皮肤病说明书外应用的回顾。
目的:本文旨在概述IL-36信号在炎症性皮肤病中的重要作用,并总结司匹利单抗的治疗潜力。我们的目标是为spesolimab的超说明书应用提供见解,并为其在治疗其他挑战性皮肤疾病中的应用提供未来的方向。材料和方法:我们在PubMed、Embase、Web of Science、MEDLINE、Scopus和Cochrane图书馆进行了全面的文献检索,以确定相关研究。对于随机对照试验,我们还检索了ClinicalTrials.gov数据库。结果:在这篇综述中,我们研究了它在治疗掌足底脓疱病、持续的埃洛珀肢端皮炎、化脓性汗腺炎、坏疽性脓皮病和急性全发性脓疱病等疾病中的适应症外应用。这篇综述还探讨了IL-36在这些疾病的病理生理中的作用,并讨论了spesolimab如何解决当前治疗难治性病例的局限性。本文总结了随机对照试验和病例报告,以强调司匹利单抗在各种炎症性皮肤状况下的疗效和耐受性。我们强调了缺乏标准化治疗指南和需要更大规模的临床试验所带来的挑战。结论:本综述强调了司匹利单抗增强炎性皮肤病治疗策略的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信